



Financial Tear Sheet

CORPORATE PROFILE

Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Our product pipeline candidates utilize the hydrogel technology to provide differentiated drug delivery solutions that are designed to reduce the complexity and burden of current drop or injection regimens by creating sustained release dosage forms that can be tailored to produce the desired drug release profile. It is our intention to develop a product portfolio to overcome the issues of patient compliance and adherence by providing means of more consistent and reliable drug dosing. Ocular Therapeutix's lead product candidate, DEXTENZA™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase 3 clinical development targeting glaucoma and ocular hypertension. The Company's earlier stage assets include OTX-TIC, a sustained release travoprost intracameral implant targeting moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal implant for the treatment of retinal diseases. These injectable implants include OTX-TKI, a tyrosine kinase inhibitor (TKI), and, in collaboration with Regeneron, an extended release protein-based anti-vascular endothelial growth factor (VEGF) trap. Ocular Therapeutix's first product, ReSure® Sealant, is approved to seal corneal incisions following cataract surgery.

STOCK PERFORMANCE

OCUL (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$3.94
Change (%)	▼ 0.01 (0.25%)
Volume	289,692
52 Week Low	\$3.55
Market Cap	\$162,326,719
Rolling EPS	-1.59
PE Ratio	0
Shares Outstanding	41,095,372

Data as of 01/18/19 4:00 p.m. ET



RECENT NEWS & EVENTS

January 10, 2019 - 4:01 p.m.

[Ocular Therapeutix™ Submits Supplemental New Drug Application \(sNDA\) for DEXTENZA® \(dexamethasone ophthalmic insert\) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery](#)

January 07, 2019 - 7:09 p.m.

[Purdue Pharma L.P. and Ocular Therapeutix, Inc. Announce Initiation of Collaborative Research Activities to Evaluate Innovative Formulations for Non-Opioid Treatments for Pain](#)

December 28, 2018 - 8:00 a.m.

[Ocular Therapeutix™ Announces Completion of Debt Refinancing](#)

There are currently no events scheduled.

SEC FILINGS

Filing Date	Form
01/16/19	DEL AM
01/04/19	4
01/04/19	4
01/04/19	4

CORPORATE GOVERNANCE

Amarpreet Sawhney, Ph.D.	President, Chief Executive Officer and Chairman of the Board of Directors
Jim Fortune	Chief Operating Officer
Peter Jarrett, Ph.D.	Chief Technical Officer
Jonathan Talamo, M.D.	Chief Medical Officer
Eric Ankerud, J.D.	Executive Vice President, Clinical, Regulatory and Quality
Scott Corning	Vice President, Sales and Marketing
Art Driscoll	Vice President, Product Development

Data provided by Nasdaq. Minimum 15 minutes delayed.